Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 54.09% is 139% above its 5-year average of -138.65%, near the high end of its 5-year range (-815.65%–100.00%).
118.39% above its 12-month average of -294.14%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
54.09%
GROSS MARGIN AVG TTM
-294.14%
GROSS MARGIN AVG 3Y
-201.54%
GROSS MARGIN AVG 5Y
-138.65%
GROSS MARGIN AVG 10Y
-308.82%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+118.39%
CURRENT VS 3Y AVG
+126.84%
CURRENT VS 5Y AVG
+139.01%
CURRENT VS 10Y AVG
+117.52%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
+26.05%
vs the sector median at left
Alector, Inc.
Market Cap
$220.94M
Gross Margin
54.09%
TTM Avg
-294.14%
3Y Avg
-201.54%
5Y Avg
-138.65%
Market Cap
$239.45M
Gross Margin
99.39%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
25.00%
Market Cap
$202.05M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$244.25M
Gross Margin
79.48%
TTM Avg
71.93%
3Y Avg
74.52%
5Y Avg
72.98%
Market Cap
$245.65M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alector, Inc. (ALEC) | $220.94M | 54.09% | -294.14% | -201.54% | -138.65% |
| Compugen Ltd. (CGEN)vs › | $218.42M | 86.89% | 79.42% | 84.96% | 87.58% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $236.56M | 82.50% | 79.64% | 73.94% | 65.24% |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | 99.39% | 50.00% | 25.00% | 25.00% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $202.05M | 0.00% | 0.00% | 0.00% | 0.00% |
| High Tide Inc. (HITI)vs › | $239.89M | 25.85% | 26.57% | 27.09% | 30.11% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $244.25M | 79.48% | 71.93% | 74.52% | 72.98% |
| Galectin Therapeutics Inc. (GALT)vs › | $245.65M | 0.00% | 0.00% | 0.00% | 0.00% |
| InflaRx N.V. (IFRX)vs › | $247.45M | -24677.94% | -13289.35% | -6830.59% | -4553.73% |
Gross Margin
54.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | -99.24% |
| 2025-12-31 | -420.49% |
| 2025-09-30 | -800.31% |
| 2025-06-30 | -250.66% |
| 2025-03-31 | -815.65% |
| 2024-12-31 | 14.34% |
| 2024-09-30 | -212.85% |
| 2024-06-30 | 84.88% |
| 2024-03-31 | 85.58% |
| 2023-12-31 | 85.13% |
| 2023-09-30 | -408.60% |
| 2023-06-30 | 17.85% |
| 2023-03-31 | -213.54% |
| 2022-12-31 | -277.38% |
| 2022-09-30 | -225.53% |
| 2022-06-30 | 31.71% |
| 2022-03-31 | -116.73% |
| 2021-12-31 | -277.23% |
| 2021-09-30 | 76.39% |
| 2021-06-30 | -628.05% |
| 2021-03-31 | -1012.73% |
| 2020-12-31 | -814.55% |
| 2020-09-30 | -642.19% |
| 2020-06-30 | -974.51% |
| 2020-03-31 | -382.57% |
| 2019-12-31 | -329.30% |
| 2019-09-30 | -957.83% |
| 2019-06-30 | -270.68% |
| 2019-03-31 | -267.65% |
| 2018-12-31 | -163.50% |
| 2018-09-30 | -213.58% |
| 2018-06-30 | -136.57% |
| 2018-03-31 | -138.29% |
| 2017-12-31 | -254.30% |
| 2017-09-30 | -5117.65% |
| 2017-06-30 | -2020.46% |
| 2017-03-31 | -2020.46% |
